View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 16, 2020

Imperial College London to start Covid-19 vaccine trials

Researchers at Imperial College London in the UK are set to begin Phase I/II clinical trials of a Covid-19 vaccine candidate based on self-amplifying RNA technology.

Researchers at Imperial College London in the UK are set to begin Phase I/II clinical trials of a Covid-19 vaccine candidate based on self-amplifying RNA technology.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The trial will assess the vaccine candidate’s tolerability and effectiveness in generating an immune response.

According to researchers, the vaccine leverages synthetic strands of RNA based on the virus’ genetic material. Upon injection into the muscle, the RNA self amplifies and induces the body’s cells to produce copies of a spike protein present on the virus.

This is expected to train the immune system to identify and protect against Covid-19. The UK Government has provided more than £41m in funding to support development and clinical studies of the vaccine.

In pre-clinical safety tests and animal studies, the vaccine was observed to be safe and demonstrated encouraging signs of an effective immune response, noted the researchers.

The Phase I/II trials will assess two doses of the vaccine in 300 healthy participants. Based on the results, Phase III effectiveness studies will be performed later this year in nearly 6,000 healthy volunteers.

A viable vaccine is expected to be made available next year.

Study chief investigator Dr Katrina Pollock said: “These clinical studies are crucial in showing the safety of any new vaccine, and demonstrating the immune response it produces.

“We need to assess whether the vaccine can train the immune system to defend itself against Covid-19. The vaccine can then be rolled out to more people in the UK and beyond in pivotal trials.”

Imperial College London has established VacEquity Global Health (VGH), a new social enterprise, in collaboration with Morningside Ventures, to develop its Covid-19 vaccine.

VGH will focus on rapid development of vaccines to prevent SARS-CoV-2 infection and distribute them in the UK and internationally, including to low and middle-income countries.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena